NCT04848064
Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma
At risk: Primary completion moved 9 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 9 versions: 9 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Primary completion pushed from Oct 30, 2026 to Jul 30, 2027
- Eligibility criteria expanded, about 4 words
- Study completion pushed from Jan 30, 2027 to Jul 30, 2028
- Secondary endpoints: details revised at 4 of 6 entries
- Notable Primary completion date: Oct 30, 2025 to Oct 30, 2026
- Eligibility criteria expanded, about 39 words
- Study completion date: Jan 30, 2026 to Jan 30, 2027
- Notable Primary completion date: Apr 30, 2025 to Oct 30, 2025
- Study completion date: Apr 30, 2025 to Jan 30, 2026
- Minor Primary and study completion dates: Dec 31, 2024 to Apr 30, 2025v6
- Notable Primary completion date: Dec 31, 2023 to Dec 31, 2024v5
Show 3 earlier versionsHide 3 earlier versions
- Notable Start date changed from estimate of Nov 1, 2021 to May 6, 2022v4
- Notable Eligibility criteria expanded, about 14 wordsv3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date: Jun 1, 2021 to Nov 1, 2021
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Incidence of adverse events
Timeframe: Up to day 84
Secondary (6)
Overall response rate (ORR)
Progression free survival
Overall survival
Natural Killer (NK)-cell numerical expansion in vivo
Analysis of cytokine levels
Show 1 moreShow less
Quality of life analysis
Arms and interventions
Treatment (mogamulizumab, chemotherapy, NK cells)Experimental
Patients receive mogamulizumab IV over 60 minutes on day -7 and fludarabine IV and cyclophosphamide IV on days -5 to -3. Patients receive NK cell infusion on day 0. Patients then receive mogamulizumab IV over 60 minutes on days 0, 7, 14, and 28, then every 2 weeks thereafter in the absence of disease progression or unacceptable toxicity.
Drugs: Cyclophosphamide, Fludarabine
Biologicals: Mogamulizumab, Natural Killer Cell Therapy
Other: Quality-of-Life Assessment, Questionnaire Administration
Sites
1 site in 1 country
- Ohio State University Comprehensive Cancer CenterColumbus, Ohio, United States